U.S. health authorities said Thursday that 16- and 17-year-olds should get a booster dose of Pfizer's COVID-19 vaccine once they're six months past their last shot.
The U.S. and many other nations already were urging adults to get booster shots to pump up immunity that can wane months after vaccination, calls that intensified with the discovery of the worrisome new omicron variant.
On Thursday, the Food and Drug Administration gave emergency authorization for 16- and 17-year-olds to get a third dose of the vaccine made by Pfizer and its partner BioNTech. And hours later, the Centers for Disease Control and Prevention lifted the last barrier — saying those teens should get their booster as soon as it's time.
CDC Director Rochelle Walensky told The Associated Press the boosters are important considering that protection against infection wanes over time and “we’re facing a variant that has the potential to require more immunity to be protected.”
“Vaccination and getting a booster when eligible, along with other preventive measures like masking and avoiding large crowds and poorly ventilated spaces, remain our most effective methods for fighting COVID-19,” Dr. Janet Woodcock, acting FDA commissioner, said in a statement.
The Pfizer vaccine is the only option in the U.S. for anyone younger than 18, either for initial vaccination or for use as a booster. It’s not yet clear if or when teens younger than 16 might need a third Pfizer dose.
Vaccinations for children as young as 5 just began last month, using special low-dose Pfizer shots. By this week, about 5 million 5- to 11-year-olds had gotten a first dose.
The extra-contagious delta variant is causing nearly all COVID-19 infections in the U.S., and in much of the world. It’s not yet clear how vaccines will hold up against the new and markedly different omicron mutant. But there’s strong evidence that boosters offer a jump in protection against delta-caused infections, currently the biggest threat.
Complicating the decision to extend boosters to 16- and 17-year-olds is that the Pfizer shot -- and a similar vaccine made by Moderna -- have been linked to a rare side effect. Called myocarditis, it’s a type of heart inflammation seen mostly in younger men and teen boys.
The FDA said rising COVID-19 cases in the U.S. mean the benefits of boosters greatly outweighed the potential risk from the rare side effect, especially as the coronavirus itself can cause more serious heart inflammation.
Health officials in Israel, which already gives boosters to teens, have said the side effect continues to be rare with third doses.
A U.S. study this week offered additional reassurance. Researchers from children’s hospitals around the country checked medical records and found the rare side effect usually is mild and people recover quickly. The research was published Monday in the journal Circulation.
___
Associated Press reporter Matthew Perrone contributed to this report.
On this episode of Cheddar Innovates: Yat Labs Co-Founder breaks down how a 'Yat' is changing the way people think about their online identities; Scythe Robotics CEO explains how it's bringing innovation to the landscaping industry with its autonomous, all-electric mowers; Founder of California Cowboy discusses how its creating clothing designed for creating in-person connections with others with features like a beverage pocket, bottle opener, and conversation cards; Cheddar gets a look at Curiosity Stream's 'Beyond the Spotlight' biography series.
Amazon founder Jeffrey Bezos took to the stage at the U.N.'s COP26 Climate Summit to unveil a new plan to combat climate change, but some say it might do more harm than good. Justine Calma, Science Reporter at The Verge, joined Cheddar to discuss.
Pfizer has asked the FDA to expand authorization of COVID booster shots for all adults. The agency is expected to grant the request in the coming weeks, allowing vaccinated Americans as young as 18 to get boosted before the holidays. Dr. Bayo Curry-Winchell, Regional Clinical Director at Carbon Health, joined Cheddar to discuss.
Wood modification technology company Kebony recently raised $34 million in its latest funding round. The company's patented technology transformed sustainable softwood using leftover materials and makes it into a product that behaves like premium hardwood. The process has the potential to transform the global construction industry, as it is cost-effective and eco-friendly. Kebony CEO Norman Willemsen joined Cheddar News' Closing Bell to discuss.
Emma Searson, an author on the just-released Renewables on the Rise report and the director, 100% Renewable Campaign at Environment America, joined Cheddar to discuss the rapidly growing renewable energy sector. Between 2011 and 2020, the report shows that wind, solar, and geothermal energy production grew about 15 percent annually and that wind and solar alone account for 11 percent of electricity in the country. "There are a few really important drivers of the renewable energy progress that we're seeing all across the country," Searson said, highlighting falling prices, technology improvements, and supportive policies.
On this episode of 'Cheddar Reveals', Lydia McMullen-Laird and Samuel McMullen, co-founders of Live Zero Waste, discuss the sum of humanity's 'trash addiction' and lifestyle changes people can make to help reduce their individual trash output; Ryan Lupberger, Sustainability Pioneer and CEO of Cleancult, breaks down how Cleancult is redefining cleaning products and solutions to reduce their impact on the planet; Cheddar gets a look at Curiosity Stream's 'Going Circular.'
The U.S. has reopened its borders for fully vaccinated international visitors, ending a ban on foreign travelers that started more than a year ago. It's a welcome change for families separated by the pandemic and a sign of hope for the battered travel industry. Steve Shur, president of the The Travel Technology Association, discusses the new rules and how they could propel the travel industry into a post-pandemic boom.
